9 Meters gains as short bowel syndrome drug succeeds in mid-stage study

9 Meters Biopharma

26/09/2022 22:08

** Shares of drugmaker 9 Meters Biopharma Inc   NMTR.O  jump
25.1% to 26 cents in extended trading
    ** Co discloses positive final data from a mid-stage study
of vurolenatide, its experimental treatment for patients with
short bowel syndrome
    ** Says based on its meeting with the U.S. Food and Drug
Administration (FDA), co intends to finalize the late-stage
study protocol during Q4  urn:newsml:reuters.com:*:nACSlvN3Va
    ** Up to last close, stock had fallen ~79% YTD
 (Reporting by Akash Sriram in Bengaluru)
 ((Akash.Sriram@thomsonreuters.com; https://twitter.com/hoodieonveshti;))